Logo Image
News|Articles|May 6, 2026

Madrigal Adds RNAi Candidate ARO-PNPLA3 for Genetically Defined MASH Subgroup

Listen
0:00 / 0:00

Key Takeaways

  • Madrigal’s agreement secures exclusive rights to an RNAi candidate aimed at PNPLA3, positioning genotype-guided therapy for a molecularly defined MASH subset rather than a broad metabolic approach.
  • Reported phase 1 signals center on imaging-based hepatic fat reduction, a biologically supportive biomarker that remains insufficient to infer MASH resolution, fibrosis regression, or clinical outcomes.
SHOW MORE

Madrigal licensed Arrowhead's ARO-PNPLA3 to target PNPLA3 I148M-associated metabolic dysfunction–associated steatohepatitis, expanding options beyond approved resmetirom.

Madrigal Pharmaceuticals has licensed Arrowhead Pharmaceuticals’ RNA interference candidate ARO-patatin-like phospholipase domain-containing 3 (PNLA3) for metabolic dysfunction–associated steatohepatitis (MASH), adding a genetically targeted program to a pipeline anchored by resmetirom—the first FDA–approved drug for noncirrhotic MASH with moderate to advanced fibrosis.2,4

The agreement includes $25 million upfront and up to $975 million in development, regulatory, and sales milestones, according to Arrowhead’s announcement as reported by Fierce Biotech.1

Rationale for a Genetically Targeted Approach

The deal is notable because PNLA3 is being positioned for a molecularly defined subgroup of patients carrying the PNPLA3 I148M variant. This variant is a well-established genetic risk factor associated with hepatic steatosis and progression to steatohepatitis and fibrosis.3

In company statements, Arrowhead CEO Christopher Anzalone, PhD, emphasized Madrigal’s leadership in MASH, while Madrigal CEO Bill Sibold highlighted the potential for personalized treatment strategies targeting genetic drivers of disease progression.1

Mechanism of Action and Early Clinical Data

ARO-PNPLA3 is an RNA interference (RNAi) therapeutic designed to reduce hepatic expression of PNPLA3. The I148M variant in this gene has been linked to increased liver fat accumulation and worse clinical outcomes.3

According to company-reported data:

  • A phase 1 US study (n = 55) showed reductions in liver fat within 6 weeks, sustained through at least 24 weeks.
  • A second phase 1 study in Japan (n = 9) provided supportive findings.
  • A 46% reduction in liver fat was observed after a single dose in patients homozygous for the PNPLA3 I148M mutation.

Regulatory Context: Resmetirom Approval

In March 2024, the FDA approved resmetirom (Rezdiffra) for adults with noncirrhotic MASH and moderate to advanced fibrosis, in conjunction with diet and exercise.4

This approval was based on accelerated approval (Subpart H) using 12-month histologic endpoints from the phase 3 MAESTRO-NASH trial.2 The decision established a regulatory precedent but also highlighted ongoing uncertainties, including:

  • Treatment sequencing
  • Use in genetically defined subgroups
  • Management of incomplete responders

Pipeline Expansion and Strategic Positioning

Madrigal has been expanding beyond a single-asset strategy. According to Fidler (2026), additional 2026 transactions include:

  • Preclinical small interfering RNA (siRNA) programs from Ribo Life Science
  • A diacylglycerol acyltransferase 2 (DGAT2) inhibitor acquired from Pfizer

These programs are intended for potential combination use with Rezdiffra. In contrast, ARO-PNPLA3 is positioned as a precision medicine approach targeting a genetically defined subgroup.

Madrigal noted that approximately 30% of patients with MASH and moderate to advanced fibrosis may carry two copies of the PNPLA3 I148M mutation.

Development Uncertainty and Prior Partnerships

ARO-PNPLA3 has had a mixed development history. Johnson & Johnson previously returned rights to the asset in 2023 during pipeline restructuring.1

While this does not necessarily reflect on the underlying biology, it underscores the broader challenge in MASH drug development, where many candidates have demonstrated biomarker improvements without achieving registrational success.

Implications for the MASH Field

The significance of this transaction lies less in immediate clinical impact and more in its strategic direction. MASH is a heterogeneous disease involving metabolic, inflammatory, fibrotic, and genetic drivers.

A therapy targeting PNPLA3 may help determine whether:

  • Genetically enriched trial populations improve signal detection
  • Precision approaches translate into meaningful histologic benefit
  • Companion diagnostic strategies are feasible in this setting

These questions remain unanswered.

Future Development Considerations

Next steps for ARO-PNPLA3 will likely include:

  • Dose optimization
  • Expansion into mid-stage trials
  • Inclusion of biopsy-based endpoints
  • Integration of noninvasive biomarkers
  • More comprehensive safety reporting

Reference

  1. Fidler, B. (2026, May 5). Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal. Fierce Biotech. https://www.fiercebiotech.com/biotech/madrigal-boosts-mash-pipeline-1b-biobucks-license-arrowhead-asset
  2. Harrison, S. A., Bedossa, P., Guy, C. D., et al. (2024). A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/38324483/
  3. Romeo, S., Kozlitina, J., Xing, C., et al. (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics. https://pmc.ncbi.nlm.nih.gov/articles/PMC2597056/
  4. U.S. Food and Drug Administration. (2024, March 14). FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA. https://www.fda.gov

Related Content